Purpose: Lipoprotein-associated phospholipase A2 (Lp-PLA2) is involved in the pathogenesis of atherosclerosis, especially in advanced plaques. In the present study, the abilities of darapladib, a selective Lp-PLA2 inhibitor, and lentivirus-mediated Lp-PLA2 silencing on in ammation and atherosclerosis in apolipoprotein E-de cient mice were compared.
Despite major advances in treatment of atherosclerosis, a large number of victims of the disease, who are apparently healthy, die suddenly without prior symptoms. is observation led us to identify possible novel therapeutic targets in the treatment of atherosclerosis. An interesting target for cardiovascular drug development is lipoprotein-associated phospholipase A2 (Lp-PLA 2 , also termed platelet-activating factor acetylhydrolase, PAFAH). Lp-PLA 2 is an enzyme that plays an atherogenic role by hydrolyzing platelet activating factor (PAF) and oxidized phospholipids, resulting in the generation of two bioactive lipid mediators, lysophosphatidylcholine (LPC) and oxidized non-esteri ed fatty acid (oxNEFA), both of which play key roles in atherosclerosis [1] [2] [3] [4] [5] . Epidemiological studies have supported Lp-PLA2 as a cardiovascular risk marker independent of traditional risk factors [6] [7] [8] [9] .
Given its biology and epidemiology, Lp-PLA 2 provides an attractive target for intervention to reduce atherosclerosis. In a previous study, darapladib, a selective Lp-PLA 2 inhibitor, decreased intraplaque LPC content and reduced the necrotic core in animal models of atherosclerosis [10] . Chronic suppression of circulating Lp-PLA 2 activity with darapladib did not reduce human plaque volume nor alter plasma hs-CRP concentration in a phase II clinical study [11, 12] . In summary, experimental and epidemiological evidences are not equivocal about the potentially proatherogenic and antiatherogenic effects of darapladib [13] .
RNA interference (RNAi) has been shown to be quite ef cacious in silencing target genes in both dividing and nondividing cells [14] ; however, no studies have investigated the e ects of Lp-PLA2 silencing on the progression of atherosclerosis in mice models. In the present study, the e ects of darapladib and lentivirus-mediated Lp-PLA 2 RNAi on the progression of atherosclerosis in apolipoprotein E de cient mice were compared.
Materials and Methods

Lp-PLA 2 RNAi lentiviral vectors
Lp-PLA 2 RNAi and negative control (NC) lentivirus expressing non-targeting sequences were used (Shanghai Genepharma Co., Shanghai, China). e target sequence for Lp-PLA 2 RNAi was 5'-GCAAGCTGGAATTCTCCTTTG-3' . A scrambled shRNA sequence (5'-TTCTCCGAACGTGTCACGT-3') served as NC. Vectors were made as previously described [15, 16] . e titers averaged to 1×10 9 TU (transduction units)/ml.
Cell culture e RAW264.7 mouse macrophage cell line was routinely cultured in DMEM. When cells had grown to 90% con uence, the Lp-PLA 2 RNAi lentiviruses and lenti-scrambled-shRNA were then used to transfect RAW264.7 cells at a multiplicity of infection (MOI) of 50. Previous studies demonstrated that unstimulated macrophage cells failed to produce detectable levels of Lp-PLA 2 , while oxidized (ox)-LDL up-regulated the expression of Lp-PLA 2 in a concentration-and time-dependent manner [11] . In our preliminary cell experiments, the expression of Lp-PLA 2 reached the platform stage a er 60 μg/ml of oxLDL stimulation. erefore, the cells were pretreated with 60 μg/ml oxLDL. Next, the e ects of RNAi and darapladib on the expression of Lp-PLA 2 and matrix metalloproteinase-8 (MMP-8) were investigated using quantitative real-time PCR. Non-lentivirus-and lentivirus-containing NC shRNA transfection served as controls.
Animal protocol
Ninety six male apolipoprotein E-de cient mice received a high-fat diet (0.25% cholesterol and 15% cocoa butter) and underwent constrictive collar placement around the le common carotid artery a er anaesthesia with an intra-peritoneal injection of pentobarbital sodium (30-50 mg/kg) [17] . In brief, the common carotid arteries were dissected and a constrictive silastic collar (0.30 mm) was placed on the le common carotid artery by placement of three circumferential silk ties in all mice. Subsequently, the entry wound was closed and the animals were returned to their cage for recovery from anesthesia. Eight weeks a er surgery, the carotid collars were removed under anesthesia. e mice were randomly allocated to either the treatment group or non-treatment group (n= 48). Treatment group mice were then randomly distributed into two subgroups of 24 animals each: the darapladib group, in which darapladib was administered in the following 5 weeks at a dose of 50 mg/kg/day and the RNAi group, in which 10 8 TU (100 µl) of viral suspension was injected into the tail vein of the mice. Non-treatment group mice were also randomly distributed into two subgroups of 24 animals each: the control group had their collars removed without drug administration; the NC group received 10 8 TU (100 µl) of NC lentivirus injected into the tail vein of the mice [18] . e animal experimental protocol complied with the Animal Management Rules of the Chinese Ministry of Health (document No. 55, 2001) and was approved by the Ethics Committee of Zhengzhou University (Zhengzhou, China).
Histological analysis
All mice were sacri ced at week 13. Mice were perfused with PBS via the le ventricle.
e carotid artery was crosssectioned and stained with hematoxylin and eosin (HE); plaque collagen and lipid deposition were identi ed using Masson's trichrome and oil red O (ORO) staining, respectively.
RNA extraction and real time-PCR
Total RNA was extracted with Trizol reagent. PCR products were synthesized using SYBR Green RT-PCR Master Mix and were analyzed with a RT-PCR cycler and detection system (ABI Prism 7300 Sequence Detection System, PE Applied Biosystems, Foster City, USA). e transcript amount of β-actin was used as an internal control. uantitative values were obtained from the threshold cycle (Ct). e speci c primers are given in Table 1. e results were analyzed by the 2 -ΔΔCt method.
Western blot analysis
Carotid arteries were collected and lysed with protease inhibitor in 1 × lysis bu er on ice for 10 to 15 minutes. Homogenates were centrifuged at 12,000 g for 20 min on ice, and supernatants were collected and protein content was quanti ed using the BCA method, and then SDS-PAGE electrophoresis was performed. Proteins were transferred to PVDF membranes, membranes were blocked with 5% non-fat milk and incubated overnight with primary antibodies against Lp-PLA2, MMP-8 (Abcam, Cambridge, UK), IL-10, IL-6 and β-actin (Zhongshan, China). A er washing with TBS-T, the membranes were incubated with horseradish peroxidase (HRP)-conjugated secondary antibodies at room temperature for 60 min. Subsequently, the appropriate HRP-conjugated secondary antibodies were used, and the blots were probed and then exposed to X-ray lm. uantitative analysis was performed by ImageJ so ware and expression level was normalized to β-actin.
Plasma lipid and biological analysis
Plasma concentration of Lp-PLA2, IL-10, MMP-8, IL-6, PAF, LPC and plasma lipoprotein level were measured using commercial kits (CoWin-Bio-science, Beijing, China) following the manufacturer's recommendation.
Statistical analysis
Data are presented as mean values ± standard deviation (SD). Comparisons were made using one-way analysis of variance, followed by the Student-Newman-Keuls (SNK) post hoc tests for signi cance. All analyses involved the use of SPSS 16.0 statistical analysis so ware (SPSS, Inc., Chicago, USA). P < 0.05 was considered statistically signi cant. 
Results
E ects of darapladib and Lp-PLA 2 RNAi in vitro
A er 60 μg/ml of oxLDL pretreatment, the expression of Lp-PLA 2 increased sharply. Mouse RAW264.7 cells were then untransfected or transfected with NC lentivirus or Lp-PLA 2 RNAi lentivirus (MOI = 50) to determine their silencing eciency. Our results demonstrated that Lp-PLA 2 RNAi or darapladib inhibited the augmentation of Lp-PLA 2 and MMP-8 induced by oxLDL. In addition, darapladib decreased the mRNA expression of IL-8 in a dose-dependent manner (Figure 1 ). 
Lp-PLA 2 inhibition has no signi cant e ects on body weight and plasma lipid pro le
As expected, no signi cant di erences in the TC, TG, HDL-C and LDL-C levels were observed among all groups. Additionally, the body weights of mice were not signi cantly di erent ( Table 2 ).
E ects of Lp-PLA2 inhibition on plasma concentration of in ammatory markers
e treatment group had lower plasma concentrations of proin ammatory cytokines (IL-6, LPC and MMP-8) together with increased concentrations of anti-in ammatory cytokine (IL-10) when compared with the non-treatment group. In contrast, the plasma levels of PAF did not di er among the four subgroups. In addition, no di erence in plasma concentration of in ammatory markers was found between the darapladib group and the RNAi group ( Figure 2 ). As expected, the control group did not di er from the NC group in these markers.
E ects of Lp-PLA2 inhibition on the morphology of plaques
e relative content of collagen in plaques of the control, NC, darapladib and RNAi groups was 22.5, 22.4, 33.6 and 36.7%, respectively, and was signi cantly higher in the RNAi group than that in the darapladib group (P < 0.01). e lipid content in the plaques of the control, NC, darapladib and RNAi groups were 27.6, 27.4, 19.3 and 15.3%, respectively, and was signi cantly lower in the RNAi group than that in the darapladib group (P < 0.01). us, the treatment group showed lower lipid content and higher collagen content than the nontreatment group (Figure 3, 4) .
Fibrous cap thickness was signi cantly higher in the RNAi group than that in the darapladib and non-treatment groups (P<0.01). Cross-sectional plaque area was signi cantly lower in the RNAi group than that in the darapladib and non-treatment groups (P<0.01). Interestingly, the plaque area for the darapladib group was not signi cantly di erent from than that of the non-treatment group (P > 0.05). Taken together, these data indicate that the RNAi group showed less lipid content, lower plaque area, higher collagen content and brous cap thickness than the darapladib and non-treatment groups. Although the two treatmentswere both e ective in stabilizing atherosclerotic plaques, RNAi group exhibited reduced plaque area and enhanced plaque stability as compared to the darapladib group. Darapladib had no e ect on attenuating the atherosclerotic plaque area, although darapladib administration improved the stability of the plaque. Plaque area and composition among all groups were not statistically signi cant at week 8.
E ects of Lp-PLA2 inhibition on the expression of in ammatory genes within the plaque
Lp-PLA 2 inhibition decreased the expression of proin ammatory cytokines (MMP-8 and IL-6) and increased the expression of anti-in ammatory cytokines (IL-10) in atherosclerotic plaques. is e ect was greater with RNAi treatment. As expected, no signi cant di erences in the expression of in ammatory genes were observed between control and NC groups ( Figure 5 ). 
Discussion
In the present study, the e ects of Lp-PLA 2 inhibition by darapladib or lentivirus-mediated RNAi on the progression of atherosclerosis and associated in ammatory process following collar induced atherosclerosis in apolipoprotein E de cient mice were investigated. Both RNAi and darapladib ameliorated atherosclerosis and reduced the expression of proin ammatory cytokines, suggesting that Lp-PLA2 inhibition can exert a potentially therapeutic e ect. In addition, the benecial e ects were more pronounced in the RNAi group, indicating that Lp-PLA 2 RNAi was superior to darapladib in ameliorating atherosclerosis.
It is clear that atherosclerosis is not only a lipid disease, but a complex, intertwined, in ammatory disease [19, 20] . is possibly explains why, despite state of the art therapies, signicant residual risk of morbidity and mortality from atherosclerosis still persists [21] . is led us to identify novel risk factors as well as mediators of atherosclerosis. Lp-PLA2 is responsible for the metabolism of oxidized phospholipids to the proatherogenic mediators LPC and oxNEFA [11] , both of which contribute to in ammation and atherosclerosis [3, 11] . Given its biology and epidemiology, darapladib provides an attractive target for intervention to reduce atherosclerosis. Previous studies demonstrated that darapladib decreased intraplaque LPC content, attenuated the expression of in ammatory genes, and reduced necrotic core formation in animal models of atherosclerosis [10, 22] ; however, darapladib did not reduce human plaque volume in a phase II clinical study [11, 12] . In summary, experimental and epidemiological evidence is not equivocal about the e ects of darapladib [13, 18, 23] . RNAi has been shown to be quite ef cacious in silencing target genes in both dividing and non-dividing cells [14] , as such we employed the two methods (darapladib and RNAi) and compared the distinct mechanisms involved in atherosclerosis. Our data indicate that darapladib and lentivirus-mediated Lp-PLA2 silencing is equally e ective in decreasing the concentration of pro-in ammatory cytokines in plasma. Moreover, the reduction in the lesion expression of Lp-PLA 2 and pro-in ammatory cytokines is more prominent in the RNAi group than that in the darapladib group, supporting the idea that RNAi was superior to darapladib in attenuating the expression of Lp-PLA 2 and pro-in ammatory cytokines in plaques. Additionally, these bene cial e ects observed in the treatment groups were associated with decreased lipid contend, increased collagen content and increased brous cap thickness. is e ect was more pronounced in the RNAi group, supporting the idea that Lp-PLA2 RNAi was superior to darapladib in stabilizing atherosclerotic plaques. Furthermore, the plaque area was reduced only in the RNAi group, suggesting that plaque area is more closely related to the concentration of pro-in ammatory cytokines in plaques than to the concentration of pro-in ammatory cytokines in plasma. No signi cant di erences in body weight and plasma lipoprotein levels were found among the groups, indicating that RNAi was safe and the therapeutic e ect was independent of the plasma lipoprotein pro le. Lp-PLA 2 is present mainly on LDL in humans, whereas HDL is the preferred carrier in mice. Several lines of evidences suggest that the mouse model, with a lipoprotein pro le di erent from humans, was inadequate for studying the e ects of Lp-PLA 2 inhibition in vi o because HDL-associated Lp-PLA 2 contributed to the reduction of atherosclerosis, whereas LDLassociated Lp-PLA 2 stimulated this process [6] . Controversy exists regarding this process, as increased plasma Lp-PLA 2 has also been associated with susceptibility to atherosclerosis in mice, and coronary heart disease patient exhibit reduced LDLLp-PLA 2 mass and catalytic e ciency, suggesting a diminished ability to degrade pro-in ammatory phospholipids [24, 25] . Indeed the biological role of Lp-PLA 2 is controversial since the anti-or proatherogenic functions of this enzyme have been proposed. Lp-PLA 2 might be antiatherogenic if it hydrolyzes PAF, a well-known proinfammatory factor that contributes to in ammation and atherosclerosis [22, 26] . Despite this, individuals with reduced levels of Lp-PLA 2 activity do not display the rampant in ammatory responses anticipated from uncontrolled PAF accumulation [12] , and the acute bronchoconstrictive response to inhaled PAF does not vary in these individuals [12, 27, 28] . Moreover, there is no evidence that Lp-PLA 2 hydrolyzes PAF in vi o. In a recent study by Hu et al., darapladib did not change plasma PAF levels [22] . Similarly, intravenous administration of human recombinant Lp-PLA 2 failed to alter PAF-mediated responses or mortality in patients with asthma or septic shock [27, 29] . Finally, a recent report by Liu et al. indicated that circulating PAF is primarily cleared by PAF receptor-independent transport, rather than by intravascular hydrolysis by Lp-PLA2 in vi o. Indeed, no evidence that Lp-PLA 2 hydrolyze PAF in vi o was found in this study. Most research favors the pro-in ammatory and pro-atherogenic role of Lp-PLA 2 [24, 25, 30, 31] .
In the present investigation we observed marked e ect of Lp-PLA 2 RNAi on the expression of in ammatory cytokines. Atherosclerosis is an in ammatory disease [19] . LPC, the hydrolyzing product of Lp-PLA 2 , has been shown to contribute to in ammation and macrophages accumulation in the lesion. Macrophages are the most signi cant source of Lp-PLA 2 , MMP-8 and IL-6 in the lesion. By virtue of these processes, Lp-PLA 2 is involved in a positive-feedback loop of in ammation and atherosclerosis. MMP-8 and IL-6 are the key multifunctional cytokines which mediate in ammatory responses in atherosclerosis [32, 33, 34] . ese pro-in ammatory cytokines are known to contribute to vascular in ammation and plaque destabilization. In the present work, higher levels of MMP-8 were found in the carotid plaques of control and NC groups, and this e ect was decreased signi cantly by Lp-PLA2 RNAi.
In addition, our cell experiments demonstrated that Lp-PLA 2 RNAi inhibited the expression of MMP-8 evoked by ox-LDL.
ese results were in line with a previous study indicating that atherosclerotic lesions in MMP8-de cient mice had signicantly fewer macrophages but increased collagen content [32] . Collectively, our results suggest that Lp-PLA2 RNAi decreased the expression of pro-in ammatory cytokines, as well as increased the expression of anti-in ammatory cytokines (IL-10), thereby played an anti-atherogenic and anti-in ammatory role in the stabilization of vulnerable plaques.
Lp-PLA2 RNAi ameliorated atherosclerosis in apolipoprotein E-de cient mice. Our results were in accordance with previous studies which associated increased Lp-PLA 2 levels with in ammation and atherosclerosis; however, our results di ered from uarck et al. who reported that adenovirus-mediated Lp-PLA 2 gene transfer prevented injury-induced neointima formation in mice [18] . ese contradictions may be due to the varied penetrance of pro-atherogenic stimuli at di erent arterial sites. In addition, distinct temporal roles for Lp-PLA 2 during lesion pathogenesis cannot be ruled out. Lp-PLA 2 is upregulated in macrophages within vulnerable and ruptured plaques, but not within stable lesions [35, 36] . As Lp-PLA 2 predominantly exists in advanced plaques, it may play an important role in advanced lesions and the determination of plaque instability, but not at earlier stages of atherogenesis. For this reason, the duration of the current investigation was ve weeks, which is longer than the three weeks in the study by uarck et al. [18] . Lentiviral vectors provide a HIV-1-based self-inactivating lentivirus for gene therapy. A signi cant number of safety features were designed to enhance its bio-safety and to minimize its relation to human HIV-1 virus. Further research is still needed to clarify the bio-safety of the lentivirus vectors.
Limitations of the study should be considered. To begin with, the plasma concentration of Lp-PLA2 were measured only at the end of the investigation, which may not re ect the variation of Lp-PLA 2 over time. Secondly, our data demonstrated that darapladib group exhibited enhanced stabilization of carotid plaques than the control group, but the plaque area between the two groups was similar. Possible explanation for this phenomenon might be the dose of darapladib used in the present study was relatively small or that the duration of this study was not long enough to detect these variation. Further research is needed to clarify these details.
In conclusion, Lp-PLA2 inhibition was e ective in ameliorating atherosclerosis in apolipoprotein E-de cient mice, independent of the plasma lipoprotein pro le. In addition, lentivirus-mediated Lp-PLA 2 RNAi was superior to darapladib in decreasing the expression of pro-in ammatory gene, increasing the expression of anti-in ammatory gene and attenuating atherosclerosis. Our work indicated that Lp-PLA 2 RNAi provided a novel therapeutic approach to the treatment of atherosclerosis. 
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